| 1 |
Lv Q, Deng Y, Zhu X, et al. Effectiveness of cefoperazone-sulbactam alone and combined with tigecycline in the treatment of multi-drug resistant acinetobacter baumannii pulmonary infection[J]. J Coll Phys Surgeons Pakistan, 2020, 30(3): 332-334.
|
| 2 |
谭 莉，曾莉怡，吴 健，等. 老年患者耐碳青霉烯类鲍曼不动杆菌感染的耐药性及预后影响因素分析[J]. 中国实用医刊，2021, 48(1): 21-24.
|
| 3 |
Xia G, Jiang R. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: A retrospective analysis[J]. Med, 2020, 99(10): e19466.
|
| 4 |
王 哲，张彦平，朱建宏，等. 2018-2019年西安交通大学第二附属医院鲍曼不动杆菌的分布及耐药性分析[J]. 现代药物与临床，2020, 35(11): 155-160.
|
| 5 |
卯 建，单 斌，宋贵波，等. 多重耐药鲍曼不动杆菌血流感染的危险因素和预后分析[J]. 中国感染与化疗杂志，2020, 20(1): 17-23.
|
| 6 |
Rasid AM, Tugba S, Sevda Y. Successful treatment of extreme drug resistant Acinetobacter baumannii infection following a liver transplant[J]. J Infect Devel Countr, 2020, 14(4): 408-410.
|
| 7 |
薛志平. 替加环素与米诺环素分别联合头孢哌酮钠舒巴坦钠治疗PDR-Ab感染老年重症肺炎患者的疗效比较[J]. 云南医药，2020, 41(3): 76-78.
|
| 8 |
Oliveira PR, Carvalho VC, Saconi ES, et al. Tigecycline versus colistin in the treatment of carbapenem-resistant acinetobacter baumannii complex osteomyelitis[J]. J Bone Joint Infect, 2020, 5(2): 60-66.
|
| 9 |
Jaiswal B, Timalsina L, Karki S, et al. Minimum inhibitory concentration of tigecycline on acinetobacter in burn patients[J]. J Nepal Health Res Council, 2020, 18(3): 431-435.
|
| 10 |
付晓微，史学良. 替加环素对泛耐药鲍曼不动杆菌肺部感染患者WBC，PCT，CRP的影响[J]. 现代医学与健康研究电子杂志，2020, 4(1): 43-44.
|
| 11 |
韦恩帅，李秀珍. 替加环素联合头孢哌酮舒巴坦治疗多重耐药鲍曼不动杆菌血流感染一例报道[J]. 临床合理用药杂志，2020, 13(15): 158-159.
|
| 12 |
Abdallah M, Alsaleh H, Baradwan A, et al. Intraventricular tigecycline as a last resort therapy in a patient with difficult-to-treat healthcare-associated acinetobacter baumannii ventriculitis: a case report[J]. SN Comprehen Clin Med, 2020, 2(2): 1-5.
|
| 13 |
毛洪宾，何 明，和素娜. 泛耐药鲍曼不动杆菌LPS脂质A基因突变介导多黏菌素耐药及治疗方案调整[J]. 四川大学学报(医学版), 2021, 52(1): 124.
|
| 14 |
Gajic I, Ranin L, Kekic D, et al. Tigecycline susceptibility of multidrug-resistant Acinetobacter baumannii from intensive care units in the western balkans[J]. Acta Microbiol Immunol Hungarica, 2020, 67(3): 1-6.
|
| 15 |
Gulen TA, Imre A, Demi L, et al. Acinetobacter baumannii infections and antibiotic resistance in hospitalized patients in an education and research hospital: a six-year analysis[J]. Flora J Infect Dis Clin Microbiol, 2021, 25(4): 563-571.
|
| 16 |
Li Y, Xie J, Chen L, et al. Treatment efficacy of tigecycline in comparison to cefoperazone/sulbactam alone or in combination therapy for carbapenenm-resistant Acinetobacter baumannii infections[J]. Pakistan J Pharmaceut Sci, 2020, 33(1): 161-168.
|
| 17 |
Nguyen HT, Morshed MT, Vuong D, et al. Evaluation of benzguinols as next-generation antibiotics for the treatment of multidrug-resistant bacterial infections[J]. Antibiotics, 2021, 10(6): 727.
|
| 18 |
史学良. 替加环素对泛耐药鲍曼不动杆菌肺部感染患者WBC，PCT，CRP的影响[J/CD]. 现代医学与健康研究(电子版), 2020, 4(1): 39-40.
|
| 19 |
刘莉莉. 头孢哌酮舒巴坦联合替加环素治疗泛耐药鲍曼不动杆菌肺炎的疗效观察[J]. 临床合理用药杂志，2020，13(25): 56-57.
|
| 20 |
林宇斌，温建立. 替加环素治疗多重或泛耐药鲍曼不动杆菌引起的重症肺炎的疗效分析[J]. 云南医药，2020, 41(6): 12-14.
|
| 21 |
邵敏建，高 蕾，钱 倩，等. 替加环素治疗重症肺炎不良反应分析[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(5): 550-554.
|
| 22 |
周 颖，张 吉，罗 璨. 替加环素治疗心脏外科术后泛耐药鲍曼不动杆菌感染的回顾性病例分析[J]. 药物流行病学杂志，2020, 29(11): 23-26+50.
|
| 23 |
王梦鹤，明德松. 替加环素和头孢哌酮/舒巴坦钠单独及联合治疗泛耐药鲍曼不动杆菌感染的经济学分析[J]. 检验医学与临床，2020, 17(10): 115-118.
|